Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment.

Gane, Edward; Lawitz, Eric; Pugatch, David; Papatheodoridis, Georgios; Bräu, Norbert; Brown, Ashley; Pol, Stanislas; Leroy, Vincent; Persico, Marcello; Moreno, Christophe; Colombo, Massimo; Yoshida, Eric M; Nelson, David R; Collins, Christine; Lei, Yang; Kosloski, Matthew; Mensa, Federico J

Gane, Edward; Lawitz, Eric; Pugatch, David; Papatheodoridis, Georgios; Bräu, Norbert; Brown, Ashley; Pol, Stanislas; Leroy, Vincent; Persico, Marcello; Moreno, Christophe; Colombo, Massimo; Yoshida, Eric M; Nelson, David R; Collins, Christine; Lei, Yang; Kosloski, Matthew; Mensa, Federico J.

Affiliation

Gane E; From the Liver Unit, Auckland City Hospital, Auckland, New Zealand (E.G.); the Texas Liver Institute, University of Texas Health, San Antonio (E.L.); AbbVie, North Chicago, IL (D.P., C.C., Y.L., M.K., F.J.M.); the Academic Department of Gastroenterology, Medical School of National and Kapodistrian U
Lawitz E; From the Liver Unit, Auckland City Hospital, Auckland, New Zealand (E.G.); the Texas Liver Institute, University of Texas Health, San Antonio (E.L.); AbbVie, North Chicago, IL (D.P., C.C., Y.L., M.K., F.J.M.); the Academic Department of Gastroenterology, Medical School of National and Kapodistrian U
Pugatch D; From the Liver Unit, Auckland City Hospital, Auckland, New Zealand (E.G.); the Texas Liver Institute, University of Texas Health, San Antonio (E.L.); AbbVie, North Chicago, IL (D.P., C.C., Y.L., M.K., F.J.M.); the Academic Department of Gastroenterology, Medical School of National and Kapodistrian U
Papatheodoridis G; From the Liver Unit, Auckland City Hospital, Auckland, New Zealand (E.G.); the Texas Liver Institute, University of Texas Health, San Antonio (E.L.); AbbVie, North Chicago, IL (D.P., C.C., Y.L., M.K., F.J.M.); the Academic Department of Gastroenterology, Medical School of National and Kapodistrian U
Bräu N; From the Liver Unit, Auckland City Hospital, Auckland, New Zealand (E.G.); the Texas Liver Institute, University of Texas Health, San Antonio (E.L.); AbbVie, North Chicago, IL (D.P., C.C., Y.L., M.K., F.J.M.); the Academic Department of Gastroenterology, Medical School of National and Kapodistrian U
Brown A; From the Liver Unit, Auckland City Hospital, Auckland, New Zealand (E.G.); the Texas Liver Institute, University of Texas Health, San Antonio (E.L.); AbbVie, North Chicago, IL (D.P., C.C., Y.L., M.K., F.J.M.); the Academic Department of Gastroenterology, Medical School of National and Kapodistrian U
Pol S; From the Liver Unit, Auckland City Hospital, Auckland, New Zealand (E.G.); the Texas Liver Institute, University of Texas Health, San Antonio (E.L.); AbbVie, North Chicago, IL (D.P., C.C., Y.L., M.K., F.J.M.); the Academic Department of Gastroenterology, Medical School of National and Kapodistrian U
Leroy V; From the Liver Unit, Auckland City Hospital, Auckland, New Zealand (E.G.); the Texas Liver Institute, University of Texas Health, San Antonio (E.L.); AbbVie, North Chicago, IL (D.P., C.C., Y.L., M.K., F.J.M.); the Academic Department of Gastroenterology, Medical School of National and Kapodistrian U
Persico M; From the Liver Unit, Auckland City Hospital, Auckland, New Zealand (E.G.); the Texas Liver Institute, University of Texas Health, San Antonio (E.L.); AbbVie, North Chicago, IL (D.P., C.C., Y.L., M.K., F.J.M.); the Academic Department of Gastroenterology, Medical School of National and Kapodistrian U
Moreno C; From the Liver Unit, Auckland City Hospital, Auckland, New Zealand (E.G.); the Texas Liver Institute, University of Texas Health, San Antonio (E.L.); AbbVie, North Chicago, IL (D.P., C.C., Y.L., M.K., F.J.M.); the Academic Department of Gastroenterology, Medical School of National and Kapodistrian U
Colombo M; From the Liver Unit, Auckland City Hospital, Auckland, New Zealand (E.G.); the Texas Liver Institute, University of Texas Health, San Antonio (E.L.); AbbVie, North Chicago, IL (D.P., C.C., Y.L., M.K., F.J.M.); the Academic Department of Gastroenterology, Medical School of National and Kapodistrian U
Yoshida EM; From the Liver Unit, Auckland City Hospital, Auckland, New Zealand (E.G.); the Texas Liver Institute, University of Texas Health, San Antonio (E.L.); AbbVie, North Chicago, IL (D.P., C.C., Y.L., M.K., F.J.M.); the Academic Department of Gastroenterology, Medical School of National and Kapodistrian U
Nelson DR; From the Liver Unit, Auckland City Hospital, Auckland, New Zealand (E.G.); the Texas Liver Institute, University of Texas Health, San Antonio (E.L.); AbbVie, North Chicago, IL (D.P., C.C., Y.L., M.K., F.J.M.); the Academic Department of Gastroenterology, Medical School of National and Kapodistrian U
Collins C; From the Liver Unit, Auckland City Hospital, Auckland, New Zealand (E.G.); the Texas Liver Institute, University of Texas Health, San Antonio (E.L.); AbbVie, North Chicago, IL (D.P., C.C., Y.L., M.K., F.J.M.); the Academic Department of Gastroenterology, Medical School of National and Kapodistrian U
Lei Y; From the Liver Unit, Auckland City Hospital, Auckland, New Zealand (E.G.); the Texas Liver Institute, University of Texas Health, San Antonio (E.L.); AbbVie, North Chicago, IL (D.P., C.C., Y.L., M.K., F.J.M.); the Academic Department of Gastroenterology, Medical School of National and Kapodistrian U
Kosloski M; From the Liver Unit, Auckland City Hospital, Auckland, New Zealand (E.G.); the Texas Liver Institute, University of Texas Health, San Antonio (E.L.); AbbVie, North Chicago, IL (D.P., C.C., Y.L., M.K., F.J.M.); the Academic Department of Gastroenterology, Medical School of National and Kapodistrian U
Mensa FJ; From the Liver Unit, Auckland City Hospital, Auckland, New Zealand (E.G.); the Texas Liver Institute, University of Texas Health, San Antonio (E.L.); AbbVie, North Chicago, IL (D.P., C.C., Y.L., M.K., F.J.M.); the Academic Department of Gastroenterology, Medical School of National and Kapodistrian U

N Engl J Med ; 377(15): 1448-1455, 2017 10 12.

Article in En | MEDLINE | ID: mdl-29020583

Subject(s)

Antiviral Agents/therapeutic use; Benzimidazoles/therapeutic use; Hepacivirus/genetics; Hepatitis C, Chronic/drug therapy; Quinoxalines/therapeutic use; Renal Insufficiency, Chronic/complications; Sulfonamides/therapeutic use; Adult; Aged; Aged, 80 and over; Aminoisobutyric Acids; Antiviral Agents/adverse effects; Benzimidazoles/adverse effects; Cyclopropanes; Drug Combinations; Female; Genotype; Hepacivirus/isolation & purification; Hepatitis C, Chronic/complications; Humans; Lactams, Macrocyclic; Leucine/analogs & derivatives; Male; Middle Aged; Proline/analogs & derivatives; Pyrrolidines; Quinoxalines/adverse effects; RNA, Viral/blood; Sulfonamides/adverse effects; Viral Load

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antiviral Agents / Quinoxalines / Sulfonamides / Benzimidazoles / Hepacivirus / Hepatitis C, Chronic / Renal Insufficiency, Chronic Type of study: Clinical_trials Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: N Engl J Med Year: 2017 Type: Article

Fulltext

XML

PubMed Links

Search on Google